Today, our drug candidates are focused on treating rare, genetic metabolic diseases, with other major diseases on the horizon.

Synlogic is currently developing medicines that address disease from a base of operation in the gut microbiome using our synthetic biotics approach.

  • Our proprietary pipeline includes synthetic biotic therapeutics for the treatment of inborn errors of metabolism (IEM).
  • In collaboration with partners, we will apply our proprietary platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS.



(Click to enlarge)